Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics Plc ADR (NQ: BCYC )

24.96 +0.26 (+1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 367,505
Open 24.10
Bid (Size) 24.96 (6)
Ask (Size) 25.04 (6)
Prev. Close 24.70
Today's Range 23.79 - 25.28
52wk Range 12.54 - 28.67
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire

Performance

YTD
+35.36%
+35.36%
1 Month
+1.55%
+1.55%
3 Month
+7.63%
+7.63%
6 Month
+9.04%
+9.04%
1 Year
+77.65%
+77.65%

More News

Read More
Navigating 11 Analyst Ratings For Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals
From Bicycle Therapeutics plc
Via Business Wire
In-Depth Examination Of 5 Analyst Recommendations For Bicycle Therapeutics
Via Benzinga
The Latest Analyst Ratings For Bicycle Therapeutics
Via Benzinga
Bicycle Therapeutics to Present Radiopharmaceuticals Data at European Association of Nuclear Medicine 2024 Congress
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
BCYC: A Promising Play In The Biotech Sector
Via Talk Markets
Topics ETFs
Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
Via Benzinga
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Pharmacokinetic and Safety Evaluation of Lead BTC® Molecules in Phase 1/2 Trials at the 2024 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Gold Falls Sharply; US Composite PMI Surges In May
Via Benzinga
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
From Bicycle Therapeutics plc
Via Business Wire
BCYC Stock Earnings: Bicycle Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.